Clinical trial · Observational
Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids
Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers
- timeFrame
- 24 months
- description
- Measurement of the phagocytic capacity
- measure
- Antitumor activity of the CAR-macrophages compared to non-modified macrophages
- timeFrame
- 24 months
- description
- Measurement of the phagocytic capacity
Secondary outcomes (1)
- measure
- Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients
- timeFrame
- 24 months
- description
- Measurement of the phagocytic capacity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female aged 18 years or more * Histologically confirmed breast cancer at any stage * Requiring surgery or tumor biopsy as standard of care * Any or no systemic treatment * Signed informaed consent * Health insurance coverage Exclusion Criteria: * Opposed to biospecimen collection
References
Publications (0)
Data not yet available